NCT04200417

Chemoembolization for Lung Tumors

Phase I Study of Transarterial Chemoembolization of Lung Metastases

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to determine if it is safe to perform lung chemoembolization and if the lung chemoembolization procedure can successfully deliver chemotherapy to lung tumors.

Conditions

• Lung Metastases
• Endobronchial Metastases
• Pleural Metastases
• Mediastinal Metastases

Interventions

Type	Name	Description
PROCEDURE	Chemoembolization	Chemoembolization will be performed via the artery (bronchial, non-bronchial systemic, or pulmonary) that shows the greatest tumor enhancement on angiography. Chemoembolization will be performed using a lipiodol / mitomycin emulsion, followed by spherical particles.
DRUG	Mitomycin C	Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
DRUG	Lipiodol	Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
DRUG	Embospheres	Embospheres are non-resorbable spherical microspheres (trisacryl gelatin) that are FDA-approved for embolization of hypervascular tumors.

Timeline

• Start date: 2019-12-13
• Primary completion: 2022-04-19
• Completion: 2022-04-19
• First posted: 2019-12-16
• Last updated: 2025-05-16

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study